Lusvertikimab  (Synonyms: 芦维奇单抗; OSE-127)

Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

OSE-127 (4 天) 可阻断 IL7 依赖性 ALL 细胞系和患者来源的异种移植 (PDX) 样本中的 STAT5 磷酸化^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

当相应的对照小鼠显示出明显白血病的临床症状时，OSE-127 处理的小鼠体内 21/22 (95%) PDX 样本显示外周血 (PB) 母细胞减少^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2375835-91-7

液体

Colorless to light yellow

芦维奇单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Lennart Lenk, et al. The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action. ACUTE LYMPHOBLASTIC LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS| NOVEMBER 15, 2022.

  [2]. Elodie Rivière,, et al. Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. Arthritis Rheumatol. 2021 Apr;73(4):631-640.  [Content Brief]